Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2004-03-02
2009-12-29
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C530S300000, C530S350000, C435S069100, C435S069700, C435S320100, C536S023100, C536S023700
Reexamination Certificate
active
07638136
ABSTRACT:
The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof fromS. pyogenes, methods for isolating such antigens and specific uses therefore.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: A 1924/2001 (2003-06-01), None
patent: 2045869 (1991-12-01), None
patent: A-0 464 533 (1992-01-01), None
patent: WO0234771 (2002-02-01), None
patent: 96/02555 (1996-02-01), None
patent: 97/30721 (1997-08-01), None
patent: 99/38528 (1999-08-01), None
patent: 01/24822 (2001-04-01), None
patent: 01/54720 (2001-08-01), None
patent: 01/93903 (2001-12-01), None
patent: 01/93905 (2001-12-01), None
patent: 02/05448 (2002-01-01), None
patent: 02/13857 (2002-02-01), None
patent: 02/059148 (2002-08-01), None
(Ellis, R.W. (Chapter 29 of “Vaccines” Plotkin, 5.A. et al. (eds) published by W. B. Saunders company (Philadelphia) in 1988, especially p. 571.
Berneman et al Infect Immun. 1998, 66, 4163-4168.
Accession No. ABP25483.
Colman et al (Research in Immunology, 1994; 145(1): 33-36.
Abaza et al. Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444.
Altschul, S., et al. (1990). Journal of Molecular Bology 215: 403-10.
Bennett, D.; et al. “Kinetic Characterization of the Interaction of Biotinylated Human Interleukin 5 with and Fc Chimera of its Receptors a Subunit and Development of an ELISA Screening Assay using Real-Time Interaction Biosensor Analysis” Journal of Molecular Recognition 8:52-58 (1995).
Bessen, D., et al. (1988). “Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.” Infect Immun 56: 2666-2672.
Bisno, A, et d. (1987). “M proteins of group G streptococci isolated from bacteremic human infections.” Infect lmmun 55: 753-7.
Bronze, M., et al. (1988). “Protective immunity evoked by locally administered group A streptococcal vaccines in mice” J Immunol 141: 2767-2770.
Clackson, T., et al. (1991). “Making antibody fragments using phage display libraries” Nature 352: 624-8.
Cone, L., et al. Clinical and Bacteriologic Observations of a Toxic Shock-Like Syndrome Due to Streptococcus Pyogenes New Engl J Med 317: 146-9 (1987).
Cunningham, M. (2000). “Pathogenesis of Group A Streptococcal Infections” Clin Microbiol Rev 13: 470-511.
Devereux, J., et al. (1984). “A comprehensive set of sequence analysis programs for the VAX” Nucleic acids research 12: 387-95.
Doherty, E., et al. “Ribozyme Structures and Mechanisms ” Annu Rev Biophys Biomol Struct 30: 457-475 (2001).
Eisenbraun, M., et al. “Examination of Parameters Affecting the Elicitation of Humoral Immune Responses by Particle Bombardment-Mediated Genetic Immunization” DNA Cell Bio112.791-7 (1993).
Enright M., et al. (2001) “Multilocus Sequence Typing of Streptococcus pyogenes and the Relationships between emm Type and Clone” Inf. Immun. 69: 2416-27.
Etz, H., et al. (2001). “Bacterial Phage Receptors, Versatile Tools for Display of Polypeptides on the Cell Surface” J Bacteriol 183: 6924-35.
Fenderson, P., et al. (1989). “Tropomyosin shares immunologic epitopes with group A streptococcal M proteins” J Immunol 142: 2475-2481.
Fischetti, V. (1989). “Streptococcal M protein: molecular design and biological behavior” Clin Microbiol Rev 2: 285-314.
Ganz, T. (1999). Science 286: 420-421.
Georgiou, G. (1997). “Display of heterologous proteins on the surface of microorganisms: From the screening of combinatorial libraries to live recombinant vaccines” Nature Biotechnology 15: 29-34.
Guzrnan, C., et al. (1999). “Protective Immune Response against Streptococcus pyogenes in Mice after Intranasal Vaccination with the Fibronectin-Binding Protein Sfbl” J Infect Dis 179: 901-6.
Hashemzadeh-Bonehi, L., et al. “MicroCorrespondence” Mol Microbiol 30: 676-678 (1998).
Vittali et al., “PCR M Typing: a New Method for Rapid Typing of Group A Streptococci” Journal of Clinical Microbiology 40(2)679-681 (Feb. 2002).
Hemmer, B., et al. (1999). “Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease” Nat Med 5: 1375-82.
Hoe N., et al. (2001) “Distribution of Streptococcal Inhibitor of Complement Variants in Pharyngitis and Invasive Isolates in an Epidemic of Serotype M1 Group A Streptococcus Infection” J.M.Dis, 183: 633-9.
Hope-Simpson, R. “Streptococcus pyogenes in the throat: a study in a small population” J. Hyg (Lond) 87: 109-29 (1981).
Ji, Y., et al. (1997). “Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus” Infect lmmun 65: 2080-2087.
Johanson, K., et al. (1995). “Binding Interactions of Human Interleukin 5 with Its Receptor Subunit” J Biol Chem 270: 9459-71.
Jones, P., et al. “Replacing the complementarity-determining regions in a human antibody with those from a mouse” Nature 321: 522-5 (1986).
Kajava, A, et al. (2000). “The Net Charge of the First 18 Residues of the Mature Sequence Affects Protein Translocation across the Cytoplasmic Membrane of Gram-Negative Bacteria” J Bacterial 182: 2163-9.
Kohler, G., et al. (1975). “Continuous cultures of fused cells secreting antibody of predefined specificity” Nature 256: 495-7.
Kolaskar, A., et al. (1990). “A semi-empirical method for prediction of antigenic determinants on protein antigens” FEBS Lett 276: 172-4.
Lee, P. K (1989). “Quantification and toxicity of group A streptococcal pyrogenic exotoxins in an animal model of toxic shock syndrome-like illness.” J Clin Microbiol 27: 1890-2.
Lewin, A., et al. (2001). “Ribozyme gene therapy: applications for molecular medicine” Trends Mol Med 7: 221-8.
Marks, J., et al. (1992) “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling” Biotechnology (NY) 10: 779-83.
McCafferty, J., et al. (1990) “Phage antibodies: filamentous phage displaying antibody variable domains” Nature 348: 552-4.
Okano, H., et al. (1991) “Myelin Basic Protein Gene and the Function of Antisense RNA in Its Repression in Myelin-Deficient Mutant Mouse” J Neurochem 56: 560-7.
Orange et al., “Pneumococcal Serotypes Causing Disease in Children in Alabama” The Pediatric Infectious Disease Journal 12(3)244-246 (Mar. 1993).
Phillips-Quagliata, J., et al. (2000). “The IgA/IgM Receptor Expressed on a Murine B Cell Lymphoma Is Poly-Ig Receptor” J Immunol 165: 2544-55.
Rammensee, H., et al. (1999). “SYFPEITHI: database for MHc ligands and peptide motifs” Immunogenetics 50: 213-9.
Rosenshine, I., et al. (1992). “Tyrosine protein kinase inhibitors block invasin-promoted bacterial uptake by epithelial cells” Infect Immun 60: 2211-7.
Seeger, C., et al. (1984). “The Cloned Genome of Ground Squirrel Hepatitis Virus is Infectious in the Animal” Proc Natl Acad Sci USA 81: 5849-52.
Shibuya, A, et al. (2000). “Fc/ receptor mediates endocytosis of IgM-coated microbes” Nature Immunology 1:441-6.
Skerra, A. (1994). “Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment inEscherichia coli” Gene 151: 131-5.
Stevens, D. (1992). “Invasive Group A Streptococcus Infections” Clin Infect Dis 14: 2-11.
Tang, D., et al. (1992). “Genetic immunization is a simple method for eliciting an immune response” Nature 356: 152-4.
Tempest, P., et al., (1991). “Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo” Biotechnology (N Y) 9: 266-71.
Tourdot, S., et al. (2000). “A general stra
Gelbmann Dieter
Meinke Andreas
Nagy Eszter
Winkler Birgit
Baskar Padma V
Fulbright & Jaworski L.L.P.
Intercell AG
Mondesi Robert B
LandOfFree
Streptococcus pyogene antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcus pyogene antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcus pyogene antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149271